SCHEMBL6875147

SCHEMBL6875147

CC(C)CON(Cc1ccc(F)cc1)C(=O)/C=C(\O)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.38
SLC6A3 Q01959 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
SLC6A4 P31645 1/20 0.38
HTR2A P28223 8/20 0.36
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
ABCB11 O95342 1/20 0.35
CYP1A2 P05177 1/20 0.35
ADRB2 P07550 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
DRD1 P21728 1/20 0.35
TBXA2R P21731 1/20 0.35
HTR2C P28335 1/20 0.35
GPR183 P32249 1/20 0.35
CYP2C19 P33261 1/20 0.35
ADRA1A P35348 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6875148 1.00 SLC6A2 (0.38) SLC6A2SLC6A3TDP1SLC6A4HTR2A
SCHEMBL6076423 0.89 CA12 (0.38) SLC6A2SLC6A3TDP1SLC6A4HTR2A
SCHEMBL6076427 0.89 CA12 (0.38) SLC6A2SLC6A3TDP1SLC6A4HTR2A
SCHEMBL6881199 0.86 RIPK1 (0.39) TDP1MEN1KMT2A
SCHEMBL6881196 0.86 RIPK1 (0.39) TDP1MEN1KMT2A
SCHEMBL6871267 0.83 BCL2A1 (0.36) TDP1KMT2ACA12CA9
SCHEMBL6871265 0.83 BCL2A1 (0.36) TDP1KMT2ACA12CA9
SCHEMBL3682001 0.83 TDP1 (0.39) TDP1CA12CA7CA9CA14
SCHEMBL5797871 0.83 TDP1 (0.39) TDP1CA12CA7CA9CA14
SCHEMBL3681999 0.83 TDP1 (0.39) TDP1CA12CA7CA9CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1467695-A2 HIV INTEGRASE INHIBITORS Bristol-Myers Squibb Company (US) 2004-10-20 EP disclosed
US-6777440-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-08-17 US disclosed
US-20030176495-A1 HIV Integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2003-09-18 US disclosed
WO-2003049690-A2 HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176495-A1 HIV Integrase inhibitors MAPT, RIF1, HPRT1 SLC6A2 575/4885SLC6A3 1502/4885TDP1 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.